drugset
drugset / Trial / NCT00662818

Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)

NCT00662818 ↗

Phase 3 Completed 165 enrolled Merck Sharp & Dohme LLC
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of telcagepant in the treatment of acute migraine in participants with stable vascular disease. Acetaminophen/paracetamol (APAP) will be used as an active comparator in this study. The primary hypothesis of this study is that telcagepant 300 mg is superior to placebo.

Timeline

Start
2008-03-17
Primary completion
2009-09-02
Completion
2009-09-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Acetaminophen Small molecule 1000 mg Oral
Subject Telcagepant Small molecule 280 mg Oral
Subject Telcagepant Small molecule 300 mg Oral

Indications

heart disorder migraine disorder peripheral vascular disease transient ischemic attack